FibroScan® Probes
Fit the patient morphology with the appropriated probe
The complete non-invasive solution for advanced liver disease assessment
Powered by LSM by VCTE™, CAP™* and SSM by VCTE™ for liver fibrosis, liver steatosis and portal hypertension assessment.
The new spleen stiffness measurement (SSM by VCTE™) and the embedded ultrasound localization system enable risk stratification of patients with advanced chronic liver disease and portal hypertension.
SSM by VCTE™ is unique, patented and validated for portal hypertension assessment1. It is a new marker for non-invasive evaluation of spleen stiffness. 134 peer-reviewed publications support the use of SSM by VCTE™.
LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness2 with 3,800 international peer-reviewed publications.
CAP™ is unique patented and validated for liver steatosis assessment3,4 with 1,130 international peer-reviewed publications.
*CAP™ is available as an option.
Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.
Bibliography
1.European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.Stefanescu H, Marasco G, Calès P, et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228.
2.European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
3.Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
4.Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.
Fit the patient morphology with the appropriated probe
Enhance your FibroScan® capabilities for improved management of fatty liver patients
Optimize clinical workflows with real-time secure data transmission
Enhance FibroScan® liver disease assessment with biological markers